Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 10/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | TLR4 | O00206 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | TYMS | P04818 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.54 |
| ▸ | FOLR1 | P15328 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | GART | P22102 | 1/20 | 0.54 |
| ▸ | APEX1 | P27695 | 1/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7164303 | 0.95 | DHFR (0.64) | DHFRKDM4ETLR4MEN1ALDH1A1 | |
| SCHEMBL8445185 | 0.92 | DHFR (0.55) | DHFR | |
| SCHEMBL8521499 | 0.92 | DHFR (0.54) | DHFRKDM4ETLR4MEN1ALDH1A1 | |
| SCHEMBL8521494 | 0.92 | DHFR (0.54) | DHFRKDM4ETLR4MEN1ALDH1A1 | |
| SCHEMBL8446723 | 0.91 | DHFR (0.62) | DHFRKDM4ETLR4MEN1ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL27292117 | 0.91 | DHFR (0.54) | DHFRKDM4ETLR4MEN1ALDH1A1 | |
| SCHEMBL8447876 | 0.89 | DHFR (0.56) | DHFRKDM4ETLR4MEN1ALDH1A1 | |
| SCHEMBL8446841 | 0.89 | DHFR (0.52) | DHFRKDM4ETLR4MEN1ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL7860603 | 0.88 | DHFR (0.51) | DHFRKDM4ETLR4MEN1ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL7860600 | 0.88 | DHFR (0.51) | DHFRKDM4ETLR4MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030171376-A1 | Antiarthritic agents | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-09-11 | — | — | US | disclosed |
| US-6559149-B1 | Lesser side effects without compromise in their efficacy | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-05-06 | — | — | US | disclosed |
| EP-0632038-B1 | METHOTREXATE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2001-08-22 | — | — | EP | disclosed |
| EP-0543997-B1 | DERIVATIVES OF METHOTREXATE WITH ANTIRHEUMATIC ACTIVITY | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1999-12-08 | — | — | EP | disclosed |
| EP-0632038-A1 | METHOTREXATE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 1995-01-04 | — | — | EP | disclosed |
| US-5354753-A | Methotrexate derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1994-10-11 | — | — | US | disclosed |
| EP-0543997-A1 | NOVEL METHOTREXATE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 1993-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171376-A1 | Antiarthritic agents | BCOR, RCOR1, IL4 | DHFR 2079/4885KDM4E 1388/4885TLR4 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.